Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
NCT06700044

Probiotic Supplementation During Pregnancy in Women With High-Risk Pregnancies

Led by Region Skane · Updated on 2024-12-27

150

Participants Needed

1

Research Sites

155 weeks

Total Duration

On this page

Sponsors

R

Region Skane

Lead Sponsor

I

ImmuneBiotech Medical Sweden AB

Collaborating Sponsor

AI-Summary

What this Trial Is About

Preeclampsia (PE) is a complication during pregnancy characterized by hypertension, organ damage, and inflammation, without an effective treatment. The underlying mechanisms causing the disease also remain partly unknown. In this double-blind placebo-controlled study, the effects of probiotic dietary supplement GutMagnific during pregnancy will be assessed in pregnancies with a high risk of PE as well as low risk. The hypothesis is that probiotic dietary supplement GutMagnific can prevent or reduce the inflammatory response and clinical manifestations associated with PE through counteracting imbalances in the oral and gut microbiome composition.

CONDITIONS

Official Title

Probiotic Supplementation During Pregnancy in Women With High-Risk Pregnancies

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Pregnant women aged 18 years or older
  • High risk of preeclampsia with at least 1 high-risk factor or 3 or more moderate risk factors according to Swedish guidelines
  • Low risk of preeclampsia with no high-risk factors and fewer than 3 moderate risk factors
  • Ability to provide written informed consent
Not Eligible

You will not qualify if you...

  • Participation in another clinical study
  • Use of probiotic supplements within 2 weeks before baseline or during the study
  • Use of antibiotics within the last 6 weeks
  • Current treatment with metformin, progesterone, or other medications affecting the study
  • Immunosuppression
  • Diabetes mellitus type 1 or 2
  • Inflammatory bowel disease
  • Celiac disease
  • History of bad obstetric outcomes
  • Other serious medical conditions affecting gut flora or participation
  • Language difficulties or inability to understand informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Region Skåne

Lund, Sweden, 221 85

Actively Recruiting

Loading map...

Research Team

S

Stefan R Hansson, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here